Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT03976401 is registered in ClinicalTrials.gov with Akero Therapeutics, Inc as lead sponsor.

NCT NCT03976401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03976401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Nonalcoholic Steatohepatitis (NASH)
Lead sponsor
Akero Therapeutics, Inc
Phase
Phase 2
Overall status
Completed
Start date
May 28, 2019
Completion date
January 10, 2022
Enrollment
110 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

nash - nonalcoholic steatohepatitis